Trevena (TRVN) Receiving Very Positive Media Coverage, Analysis Shows

Media headlines about Trevena (NASDAQ:TRVN) have been trending very positive recently, AlphaOne reports. The research firm, a unit of Accern, identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trevena earned a news impact score of 0.56 on AlphaOne’s scale. AlphaOne also gave news articles about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Alpha One Sentiment’s scoring:

A number of research analysts have recently issued reports on TRVN shares. FBR & Co reiterated an “outperform” rating and set a $8.00 target price (down previously from $13.00) on shares of Trevena in a research report on Wednesday, February 22nd. Cowen and Company reiterated a “buy” rating and set a $13.00 target price on shares of Trevena in a research report on Wednesday, March 22nd. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $10.00 target price (down previously from $13.00) on shares of Trevena in a research report on Thursday, February 23rd. Ladenburg Thalmann Financial Services started coverage on Trevena in a research report on Thursday, February 2nd. They set a “buy” rating and a $15.00 target price on the stock. Finally, Zacks Investment Research upgraded Trevena from a “sell” rating to a “hold” rating in a research report on Wednesday, March 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Trevena currently has an average rating of “Buy” and an average price target of $11.73.

Trevena (NASDAQ:TRVN) traded down 3.74% on Thursday, reaching $2.83. The company had a trading volume of 217,491 shares. Trevena has a 52-week low of $2.77 and a 52-week high of $8.03. The company’s market capitalization is $164.99 million. The company’s 50-day moving average is $3.25 and its 200-day moving average is $4.93.

Trevena (NASDAQ:TRVN) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.19. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. Equities analysts anticipate that Trevena will post ($1.51) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally published by sleekmoney and is owned by of sleekmoney. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://sleekmoney.com/trevena-trvn-receiving-very-positive-media-coverage-analysis-shows/1853014.html.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

12 Month Chart for NASDAQ:TRVN

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/trevena-trvn-receiving-very-positive-media-coverage-analysis-shows/1853014.html

Receive News & Ratings for Trevena Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *